摘要
目的探讨多西他赛、奥沙利铂、替吉奥联合治晚期胃癌患者的临床疗效。方法回顾分析晚期胃癌患者227例,其中观察组使用多西他赛、奥沙利铂、替吉奥3种药物联合化疗,共127例;对照组使用奥沙利铂、替吉奥2种药物联合化疗,共100例,并比较分析两组患者的临床疗效、免疫功能和不良反应。结果两组患者有效率比较无统计学差异(P>0.05),但观察组的疾病控制率(83%)和中位生存时间(10个月)均显著优于对照组(P<0.05)。两组治疗前后CD3^+无明显变化(P>0.05)。与治疗前相比,两组患者治疗后的CD4^+、CD4^+/CD8^+水平均显著升高,有统计学意义(P<0.05),CD8^+无统计学差异(P>0.05);与对照组相比,观察组患者治疗后的CD4^+、CD4^+/CD8^+水平均显著升高,有统计学意义(P<0.05)。观察组患者的不良反应均为Ⅰ~Ⅲ度,不影响治疗,对照组中有3例患者的脱发为Ⅳ度,经对症治疗后缓解,其余均为Ⅰ~Ⅲ度;两组不良反应中,除恶心呕吐和肝功能损害无差异外,其余均有显著差异,且观察组发生率显著低于对照组(P<0.05)。观察组化疗平均周期为3.3个月,对照组为3.1个月(P=0.037),观察组和对照组的部分缓解率分别为47.2%和43.0%。疾病控制率分别为87.4%和81.0%;两组中位总生存期比较无明显差异(观察组为7.3个月,对照组为7.0个月,P=0.63),1年生存率(观察组为34%,对照组为31%)。结论多西他赛、奥沙利铂、替吉奥三药联合化疗可提高晚期胃癌患者的临床疗效,增强患者免疫功能,同时降低不良反应的发生,可在临床推广使用。
Objective To investigate the clinical efficacy of docetaxel, oxaliplatin and S-1 in the treatment of advanced gastric cancer. Methods A total of 227 patients with advanced gastric cancer were retrospectively analyzed. The observation group （127 cases ）was treated with doeetaxel,oxaliplatin and S-1 combined with chemotherapy. The control group （100 cases） was treated with oxaliplatin and S-1 combined with chemotherapy, and clinical efficacy, immune function and adverse reactions of the 2 groups were compared. Results The disease control rate （83%） and median survival time （10 months） were significantly better than those of the control group （ P 〈 0.05 ）. There was no significant difference between the 2 groups （ P 〉 0.05 ）. There was no significant change in CD3^＋ before and after treatment （ P 〉 0.05 ）. CD4^＋/CD8^＋ levels were significantly higher in the 2 groups than those before treatment （ P 〈 0.05 ）. There was no significant difference between the 2 groups （ P 〉 0.05 ）. Compared with the control group, The levels of CD4 ^＋ , CD4 ^＋ / CD8 ^＋ in the observation group were significantly higher than those of the control group （P 〈 0.05）. The adverse effects of the observation group were Ⅰ - Ⅲ degree, did not ＇affect the treatment, the control group,3 patients with alopecia degree Ⅳ, after symptomatic treatment after remission, the rest were Ⅰ - Ⅲ degree ; There was no significant difference in nausea and vomiting and liver function damage between the 2 groups, and there was significant difference in the incidence of other adverse reactions, and that of the observation group was significantly lower than that of the control group （ P 〈 0.05 ）. The mean regimes were 3.3 months in the observation group and 3.1 months in the control group （ P = 0. 037 ）. The partial remission rates of the observation group and the control group were 47.2% and 43.0% ,respectively. Disease control rates were 87.4% and 81.0% ,respectively. There was no significant difference in the median survival time（7.3 months in the observation group ,7.0 months in the control group ,P = 0.63 ） , and 1-year survival rates （observation group： 34% , control group： 31% ） between the 2 groups. Conclusion Docetaxel, oxaliplatin and S-1 combined with chemotherapy can improve the clinical efficacy of patients with advanced gastric cancer, enhance the immune function of patients, and reduce the incidence of ad- verse reactions,it can be used in chnical practice.
出处
《实用癌症杂志》
2018年第3期443-446,457,共5页
The Practical Journal of Cancer
